Product Name |
5-HT1 Receptor |
5-HT2 Receptor |
5-HT3 Receptor |
5-HT4 Receptor |
5-HT5 Receptor |
5-HT6 Receptor |
5-HT7 Receptor |
5-HT Receptor |
Purity |
Serotonin hydrochloride |
|
|
|
|
|
|
|
|
99.97% |
SCH-23390 hydrochloride |
|
5-HT2C Receptor, Ki: 9.3 nM
|
|
|
|
|
|
|
99.91% |
Puerarin |
|
|
|
|
|
|
|
|
98.92% |
Harmine |
|
5-HT2A Receptor, Ki: 397 nM
|
|
|
|
|
|
|
99.88% |
Clozapine |
|
5-HT2A Receptor, Ki: 4 nM (Inhibitor)
|
|
|
|
|
|
|
99.97% |
Olanzapine |
|
5-HT2A Receptor, Ki: 4 nM
5-HT2C Receptor, Ki: 11 nM
|
5-HT3 Receptor, Ki: 57 nM
|
|
|
|
|
|
99.83% |
Risperidone |
|
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
99.92% |
Vortioxetine |
|
|
5-HT3A Receptor, Ki: 3.7 nM
|
|
|
|
Human 5-HT7 Receptor , Ki: 19 nM
|
|
99.81% |
Aripiprazole |
5-HT1A Receptor, Ki: 4.2 nM
|
|
|
|
|
|
|
|
99.95% |
Thioridazine hydrochloride |
|
|
|
|
|
|
|
|
99.96% |
Ondansetron |
|
|
|
|
|
|
|
|
99.37% |
Vortioxetine hydrobromide |
|
|
5-HT3A Receptor, Ki: 3.7 nM
|
|
|
|
5-HT7 Receptor, Ki: 19 nM
|
|
99.91% |
GTS-21 dihydrochloride |
|
|
5-HT3A Receptor, IC50: 3.1 μM
|
|
|
|
|
|
99.92% |
Vilazodone Hydrochloride |
|
|
|
|
|
|
|
|
99.94% |
Volinanserin |
|
5-HT2 Receptor, Ki: 0.36 nM
|
|
|
|
|
|
|
99.76% |
SB-269970 hydrochloride |
|
|
|
|
|
|
|
|
98.62% |
WAY-100635 |
5-HT1A Receptor, pIC50: 8.87
5-HT1A Receptor, pA2: 9.71
|
|
|
|
|
|
|
|
99.51% |
Amitriptyline hydrochloride |
5-HT1A Receptor, IC50: 450 nM
5-HT1B Receptor, IC50: 40 nM
|
5-HT2A Receptor, IC50: 4 nM
5-HT2B Receptor, IC50: 40 nM
5-HT2C Receptor, IC50: 6 nM
|
|
|
|
|
|
|
98.91% |
BW-723C86 |
|
|
|
|
|
|
|
|
99.80% |
Cisapride |
|
|
|
5-HT4 Receptor, EC50: 0.14 μM
|
|
|
|
|
99.72% |
Pimavanserin |
|
5-HT2A Receptor, pIC50: 8.7
|
|
|
|
|
|
|
99.86% |
Ketanserin |
|
|
|
|
|
|
|
|
99.89% |
Brexpiprazole |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
99.85% |
PCPA methyl ester hydrochloride |
|
|
|
|
|
|
|
|
99.89% |
8-OH-DPAT |
5-HT1A Receptor, pIC50: 8.19
|
|
|
|
|
|
5-HT7 Receptor, Ki: 466 nM
|
|
99.26% |
Vilazodone |
|
|
|
|
|
|
|
|
99.84% |
Pindolol |
|
|
|
|
|
|
|
|
99.91% |
Quetiapine |
5-HT1A Receptor, pKi: 5.74
5-HT1A Receptor, pEC50: 4.77
|
5-HT2A Receptor, pKi: 7.54
5-HT2C Receptor, pKi: 5.55
|
|
|
|
|
|
|
99.88% |
SEP-363856 hydrochloride |
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
|
|
|
|
5-HT7 Receptor, EC50: 6.7 μM
|
|
99.57% |
Tegaserod maleate |
|
5-HT2B Receptor (Antagonist)
|
|
|
|
|
|
|
99.93% |
Prucalopride |
|
|
|
5-HT4A Receptor, pKi: 8.6
5-HT4B Receptor, pKi: 8.1
|
|
|
|
|
99.81% |
DOI hydrochloride |
|
Human 5-HT2A Receptor, Ki: 0.7 nM
Human 5-HT2C Receptor, Ki: 2.4 nM
human 5-HT2B Receptor, Ki: 20 nM
|
|
|
|
|
|
|
99.61% |
SB 242084 |
|
5-HT2C Receptor, pKi: 9.0
|
|
|
|
|
|
|
99.88% |
Perphenazine |
5-HT1A Receptor, Ki: 421 nM
|
5-HT2A Receptor, Ki: 5.6 nM
|
|
|
|
5-HT6 Receptor, Ki: 17 nM
|
5-HT7 Receptor, Ki: 23 nM
|
|
99.95% |
Cariprazine |
5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
99.83% |
Agomelatine |
|
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
99.88% |
Paliperidone |
|
|
|
|
|
|
|
|
99.69% |
Alosetron Hydrochloride |
|
|
|
|
|
|
|
|
99.76% |
Cariprazine hydrochloride |
5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
99.90% |
Metergoline |
|
5-HT2A Receptor, pKi: 8.64
5-HT2B Receptor, pKi: 8.75
5-HT2C Receptor, pKi: 8.75
|
|
|
|
|
Human 5-HT7 Receptor , Ki: 16 nM
|
|
99.89% |
Lurasidone |
5-HT1A Receptor, IC50: 6.75 nM
|
|
|
|
|
|
5-HT7 Receptor, IC50: 0.495 nM
|
|
99.49% |
Ziprasidone |
Rat 5-HT1A Receptor, Ki: 3.4 nM
|
|
|
|
|
|
|
|
99.81% |
8-OH-DPAT hydrobromide |
5-HT1A Receptor, pIC50: 8.19
|
|
|
|
|
|
|
|
99.89% |
GR 113808 |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
99.96% |
Ritanserin |
|
5-HT2 Receptor, IC50: 0.9 nM
|
|
|
|
|
|
|
99.68% |
Nuciferine |
5-HT1A Receptor, EC50: 3.2 μM
|
5-HT2C Receptor, IC50: 131 nM
5-HT2A Receptor, IC50: 478 nM
5-HT2B Receptor, IC50: 1 μM
|
|
|
|
5-HT6 Receptor, EC50: 700 nM
|
5-HT7 Receptor, IC50: 150 nM
|
|
99.46% |
Ketanserin tartrate |
|
|
|
|
|
|
|
|
99.99% |
Mirtazapine |
|
5-HT2 Receptor, pKi: 8.05
|
|
|
|
|
|
|
99.94% |
Sumatriptan |
5-HT1A Receptor, Ki: 100 nM
5-HT1B Receptor, Ki: 27 nM
5-HT1D Receptor, Ki: 17 nM
5-HT1D Receptor, IC50: 7.3 nM
5-HT1B Receptor, IC50: 9.3 nM
5-HT1F Receptor, IC50: 17.8 nM
|
|
|
|
|
|
|
|
99.90% |
SB 204741 |
|
human 5-HT2B Receptor, pKi: 7.1
|
|
|
|
|
|
|
99.85% |
Alprenolol |
|
|
|
|
|
|
|
|
99.94% |
Loxapine |
|
|
|
|
|
|
|
|
99.69% |
Rotigotine |
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
|
5-HT7 Receptor, Ki: 86 nM
|
|
99.99% |
Gamma-Mangostin |
|
|
|
|
|
|
|
|
99.91% |
SB-224289 hydrochloride |
|
|
|
|
|
|
|
|
≥99.0% |
R 59-022 |
|
|
|
|
|
|
|
|
99.82% |
Methiothepin mesylate |
5-HT1A Receptor, pKd: 7.10
5-HT1B Receptor, pKd: 7.28
5-HT1C Receptor, pKd: 7.56
5-HT1D Receptor, pKd: 6.99
|
5-HT2A Receptor, pKi: 8.50
5-HT2B Receptor, pKi: 8.68
5-HT2C Receptor, pKi: 8.35
|
|
|
5-HT5A Receptor, pKd: 7.0
5-HT5B Receptor, pKd: 7.8
|
5-HT6 Receptor, pKd: 8.74
|
5-HT7 Receptor, pKd: 8.99
|
|
99.60% |
Loxapine succinate |
|
|
|
|
|
|
|
|
99.81% |
Sumatriptan succinate |
5-HT1D Receptor, Ki: 17 nM
5-HT1B Receptor, Ki: 27 nM
5-HT1A Receptor, Ki: 100 nM
5-HT1D Receptor, IC50: 7.3 nM
5-HT1B Receptor, IC50: 9.3 nM
5-HT1F Receptor, IC50: 17.8 nM
|
|
|
|
|
|
|
|
99.94% |
Alprenolol hydrochloride |
|
|
|
|
|
|
|
|
99.76% |
Tegaserod |
|
|
|
|
|
|
|
|
99.89% |
RS-127445 hydrochloride |
|
5-HT2A Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 6.4
5-HT2B Receptor, pKi: 9.5
|
|
|
|
|
|
|
99.78% |
Sertindole |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
99.92% |
Nefazodone hydrochloride |
|
5-HT2A Receptor, Ki: 5.8 nM
|
|
|
|
|
|
|
99.87% |
Asenapine maleate |
|
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 0.13 nM
|
|
99.95% |
Rotundine |
5-HT1A Receptor, IC50: 370 nM
|
|
|
|
|
|
|
|
99.96% |
Rotigotine Hydrochloride |
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
|
5-HT7 Receptor, Ki: 86 nM
|
|
99.65% |
Prucalopride succinate |
|
|
|
5-HT4A Receptor, pKi: 8.6
5-HT4B Receptor, pKi: 8.1
|
|
|
|
|
99.95% |
Mosapride citrate |
|
|
|
|
|
|
|
|
99.96% |
Cefaclor |
|
|
|
|
|
|
|
|
99.61% |
Trimipramine maleate |
|
5-HT2 Receptor, pKi: 8.10
|
|
|
|
|
|
|
99.82% |
SKF-83566 |
|
5-HT2 Receptor, Ki: 11 nM
|
|
|
|
|
|
|
99.86% |
SB-699551 |
|
|
|
|
5-HT5A Receptor, pKi: 8.3
|
|
|
|
99.53% |
Palonosetron hydrochloride |
|
|
|
|
|
|
|
|
99.96% |
Tandospirone |
5-HT1A Receptor, Ki: 27 nM
|
|
|
|
|
|
|
|
99.41% |
Pimavanserin hemitartrate |
|
5-HT2A Receptor, pIC50: 8.73
5-HT2A Receptor, pKi: 9.3
|
|
|
|
|
|
|
99.91% |
Blonanserin |
|
5-HT2A Receptor, Ki: 0.812 nM
5-HT2C Receptor, Ki: 26.4 nM
|
|
|
|
5-HT6 Receptor, Ki: 11.7 nM
|
|
|
99.62% |
Roluperidone |
|
5-HT2A Receptor, Ki: 7.53 nM
|
|
|
|
|
|
|
99.86% |
(Z)-Thiothixene |
|
|
|
|
|
|
|
|
99.84% |
Gepirone |
|
|
|
|
|
|
|
|
99.88% |
NAS-181 dimesylate |
Rat 5-HT1B Receptor, IC50: 47 nM
|
|
|
|
|
|
|
|
98.44% |
Setiptiline maleate |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
99.94% |
LP-211 |
5-HT1A Receptor, Ki: 188 nM
|
|
|
|
|
|
5-HT7 Receptor, Ki: 0.58 nM
|
|
99.61% |
Metoclopramide |
|
|
5-HT3 Receptor, IC50: 308 nM
|
|
|
|
|
|
99.94% |
Ondansetron hydrochloride dihydrate |
|
|
|
|
|
|
|
|
99.94% |
UNC9994 hydrochloride |
5-HT1A Receptor, Ki: 26 nM
|
5-HT2A Receptor, Ki: 140 nM
5-HT2B Receptor, Ki: 25 nM
5-HT2C Receptor, Ki: 512 nM
|
|
|
|
|
|
|
98.83% |
Sarpogrelate hydrochloride |
|
5-HT2A Receptor, pKi: 8.52
5-HT2B Receptor, pKi: 6.57
5-HT2C Receptor, pKi: 7.43
|
|
|
|
|
|
|
99.09% |
Buspirone |
|
|
|
|
|
|
|
|
99.86% |
Syk Inhibitor II |
|
|
|
|
|
|
|
|
98.05% |
Granisetron Hydrochloride |
|
|
5-HT3 Receptor, IC50: 17 μM
|
|
|
|
|
|
99.87% |
Eletriptan hydrobromide |
5-HT1B Receptor, Ki: 0.92 nM
5-HT1D Receptor, Ki: 3.14 nM
|
|
|
|
|
|
|
|
99.81% |
Cyproheptadine hydrochloride |
|
|
|
|
|
|
|
|
99.94% |
Norfluoxetine hydrochloride |
|
|
|
|
|
|
|
|
99.58% |
Lumateperone tosylate |
|
5-HT2A Receptor, Ki: 0.54 nM
|
|
|
|
|
|
|
99.53% |
Quetiapine hemifumarate |
5-HT1A Receptor, pKi: 5.74
5-HT1A Receptor, pEC50: 4.77
|
5-HT2A Receptor, pKi: 7.54
5-HT2C Receptor, pKi: 5.55
|
|
|
|
|
|
|
99.94% |
Piboserod |
|
|
|
|
|
|
|
|
99.09% |
SB-277011 hydrochloride |
5-HT1D Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
98.54% |
2-Methyl-5-HT |
|
|
|
|
|
|
|
|
98.73% |
Granisetron |
|
|
5-HT3 Receptor, IC50: 17 μM
|
|
|
|
|
|
99.95% |
Ansofaxine hydrochloride |
|
|
|
|
|
|
|
|
99.72% |
Lurasidone Hydrochloride |
5-HT1A Receptor, IC50: 6.75 nM
|
|
|
|
|
|
5-HT7 Receptor, IC50: 0.495 nM
|
|
99.96% |
Paliperidone palmitate |
|
|
|
|
|
|
|
|
98.41% |
Harmine hydrochloride |
|
5-HT2A Receptor, Ki: 397 nM
|
|
|
|
|
|
|
99.93% |
Ziprasidone hydrochloride monohydrate |
Rat 5-HT1A Receptor, Ki: 3.4 nM
|
|
|
|
|
|
|
|
98.11% |
5-Methoxytryptamine |
|
|
|
|
|
|
|
|
99.91% |
Asenapine |
5-HT1A Receptor, pKi: 8.6
5-HT1B Receptor, pKi: 8.4
|
5-HT2A Receptor, pKi: 10.2
5-HT2B Receptor, pKi: 9.8
5-HT2C Receptor, pKi: 10.5
|
|
|
|
|
|
|
99.62% |
Oxatomide |
|
|
|
|
|
|
|
|
99.56% |
Talipexole dihydrochloride |
|
|
|
|
|
|
|
|
99.80% |
AS19 |
5-HT1A Receptor, Ki: 89.7 nM
5-HT1B Receptor, Ki: 490 nM
5-HT1D Receptor, Ki: 6.6 nM
|
|
|
|
5-HT5 Receptor, Ki: 98.5 nM
|
|
Human 5-HT7 Receptor , IC50: 0.83 nM
Human 5-HT7 Receptor , Ki: 0.6 nM
|
|
99.85% |
JNJ-18038683 |
|
|
|
|
|
|
Rat 5-HT7 Receptor, pKi: 8.19 (in HEK293 cells )
Human 5-HT7 Receptor , pKi: 8.20 (in HEK293 cells )
|
|
99.76% |
S1RA |
|
human 5-HT2B Receptor, Ki: 328 nM
|
|
|
|
|
|
|
99.43% |
Rizatriptan benzoate |
|
|
|
|
|
|
|
|
99.94% |
Sarizotan |
5-HT1A Receptor, IC50: 6.5 nM (rat)
5-HT1A Receptor, IC50: 0.1 nM (human)
5-HT1B Receptor, IC50: 600 nM (rat)
5-HT1D Receptor, IC50: 500 nM (calf)
|
5-HT2A Receptor, IC50: 960 nM (rat, agonist site)
5-HT2A Receptor, IC50: 587 nM (human, antagonist site)
5-HT2B Receptor, IC50: 108 nM (human)
5-HT2C Receptor, IC50: 800 nM (pig)
|
5-HT3 Receptor, IC50: 3500 nM (NG 108 cells)
|
|
5-HT5A Receptor, IC50: 313 nM (human)
|
5-HT6 Receptor, IC50: 3300 nM (human)
|
5-HT7 Receptor, IC50: 10 nM (human)
|
|
98.74% |
LY310762 |
5-HT1D Receptor, Ki: 249 nM
|
|
|
|
|
|
|
|
98.68% |
Tropisetron |
|
|
5-HT3 Receptor, Ki: 5.3 nM
|
|
|
|
|
|
98.72% |
F-15599 |
5-HT1A Receptor, Ki: 3.4 nM
|
|
|
|
|
|
|
|
99.82% |
SB 258719 |
|
|
|
|
|
|
|
|
99.04% |
Tianeptine sodium salt |
|
|
|
|
|
|
|
|
99.90% |
Phenylbiguanide |
|
|
5-HT3 Receptor, EC50: 3 μM
|
|
|
|
|
|
≥98.0% |
Cyproheptadine hydrochloride sesquihydrate |
|
|
|
|
|
|
|
|
99.82% |
Ecopipam hydrochloride |
|
|
|
|
|
|
|
|
99.46% |
Xanthotoxol |
|
|
|
|
|
|
|
|
99.75% |
RU 24969 |
5-HT1B Receptor, Ki: 0.38 nM
5-HT1A Receptor, Ki: 2.5 nM
|
|
|
|
|
|
|
|
99.77% |
Dolasetron |
|
|
|
|
|
|
|
|
≥98.0% |
Tropisetron Hydrochloride |
|
|
5-HT3 Receptor, IC50: 70.1 nM
|
|
|
|
|
|
99.97% |
RS-102221 hydrochloride |
|
5-HT2C Receptor, Ki: 10 nM
|
|
|
|
|
|
|
99.33% |
TCB2 |
|
|
|
|
|
|
|
|
99.21% |
Dehydroaripiprazole |
5-HT1A Receptor, Ki: 4.2 nM
|
|
|
|
|
|
|
|
99.66% |
(+)-Norfenfluramine |
|
5-HT2B Receptor, Ki: 11.2 nM
5-HT2A Receptor, Ki: 1516 nM
5-HT2C Receptor, Ki: 324 nM
|
|
|
|
|
|
|
|
Setiptiline |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
98.04% |
LY 344864 |
human 5-HT1F Receptor, Ki: 0.006 μM
human 5-HT1A Receptor, Ki: 0.530 μM
human 5-HT1B Receptor, Ki: 0.549 μM
human 5-HT1D Receptor, Ki: 0.575 μM
human 5-HT1E Receptor, Ki: 1.415 μM
|
human 5-HT2B Receptor, Ki: 1.695 μM
Human 5-HT2A Receptor, Ki: 3.499 μM
|
Human 5-HT3A Receptor, Ki: 3.935 mM
|
|
|
|
Human 5-HT7 Receptor , Ki: 4.851 μM
|
|
98.93% |
BRL 54443 |
5-HT1E Receptor, Ki: 1.1 nM
5-HT1F Receptor, Ki: 0.7 nM
5-HT1A Receptor, Ki: 63 nM
5-HT1B Receptor, Ki: 126 nM
5-HT1D Receptor, Ki: 63 nM
|
5-HT2A Receptor, Ki: 1259 nM
5-HT2B Receptor, Ki: 100 nM
5-HT2C Receptor, Ki: 316 nM
|
|
|
|
5-HT6 Receptor, Ki: >10,000 nM
|
5-HT7 Receptor, Ki: >10,000 nM
|
|
98.97% |
SB 243213 |
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
98.97% |
Ramosetron Hydrochloride |
|
|
|
|
|
|
|
|
99.96% |
Alverine citrate |
5-HT1A Receptor, IC50: 101 nM
|
|
|
|
|
|
|
|
99.71% |
(+)-Norfenfluramine hydrochloride |
|
5-HT2B Receptor, Ki: 11.2 nM
5-HT2C Receptor, Ki: 324 nM
5-HT2A Receptor, Ki: 1516 nM
|
|
|
|
|
|
|
99.77% |
SB 242084 dihydrochloride |
|
5-HT2C Receptor, pKi: 9.0
|
|
|
|
|
|
|
99.10% |
Perospirone |
5-HT1A Receptor, Ki: 2.9 nM
5-HT1 Receptor, Ki: 18 nM
|
5-HT2A Receptor, Ki: 0.6 nM
|
|
|
|
|
|
|
99.43% |
5-HT2B antagonist-1 |
|
5-HT2B Receptor, IC50: 33.4 nM
|
|
|
|
|
|
|
99.86% |
3-Hydroxy agomelatine |
|
5-HT2C Receptor, IC50: 3.2 μM
5-HT2C Receptor, Ki: 1.8 μM
|
|
|
|
|
|
|
98.00% |
Naftidrofuryl oxalate |
|
|
|
|
|
|
|
|
98.39% |
Flesinoxan |
5-HT1A Receptor, EC50: 24 nM
|
|
|
|
|
|
|
|
99.90% |
Opiranserin hydrochloride |
|
5-HT2A Receptor, IC50: 1.3 μM
|
|
|
|
|
|
|
99.44% |
A-582941 dihydrochloride |
|
|
5-HT3 Receptor, Ki: 150 nM
|
|
|
|
|
|
99.78% |
Flibanserin |
5-HT1A Receptor, Ki: 1 nM
|
5-HT2A Receptor, Ki: 49 nM
|
|
|
|
|
|
|
99.54% |
Brilaroxazine |
5-HT1A Receptor, Ki: 1.5 nM
|
5-HT2A Receptor, Ki: 2.5 nM
5-HT2B Receptor, Ki: 0.19 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 2.7 nM
|
|
98.29% |
Iloperidone |
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 μM
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
99.97% |
Pizotifen |
|
|
|
|
|
|
|
|
98.40% |
R 59-022 hydrochloride |
|
|
|
|
|
|
|
|
98.88% |
Ocaperidone |
5-HT1A Receptor, pEC50: 7.6 (h5-HT1A)
5-HT1A Receptor, pKi: 8.08 (h5-HT1A)
|
5-HT2 Receptor, Ki: 0.14 nM
|
|
|
|
|
|
|
99.93% |
Geissoschizine methyl ether |
|
|
|
|
|
|
|
|
99.63% |
Velusetrag |
|
|
|
|
|
|
|
|
99.91% |
Naratriptan hydrochloride |
|
|
|
|
|
|
|
|
99.91% |
Tetrahydro-β-carboline |
|
|
|
|
|
|
|
|
|
SB 271046 Hydrochloride |
5-HT1D Receptor, pKi: 6.55
5-HT1A Receptor, pKi: 6.35
5-HT1B Receptor, pKi: 6.05
5-HT1F Receptor, pKi: 5.95
5-HT1E Receptor, pKi: <4.99
|
5-HT2A Receptor, pKi: 5.62
5-HT2B Receptor, pKi: 5.41
Human 5-HT2C Receptor, pKi: 5.73
|
|
5-HT4 Receptor, pKi: 5.27
|
|
5-HT6 Receptor, pKi: 8.92-9.02
|
5-HT7 Receptor, pKi: 5.39
|
|
99.93% |
Asenapine hydrochloride |
|
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 0.13 nM
|
|
99.95% |
Befiradol |
|
|
|
|
|
|
|
|
99.20% |
Befiradol hydrochloride |
|
|
|
|
|
|
|
|
99.93% |
NAN-190 hydrobromide |
|
|
|
|
|
|
|
|
99.11% |
Mirtazapine-d3 |
|
|
|
|
|
|
|
|
98.55% |
GR 125743 |
human 5-HT1B Receptor, pKi: 8.85
human 5-HT1D Receptor, pKi: 8.31
|
|
|
|
|
|
|
|
99.84% |
Masupirdine mesylate |
|
|
|
|
|
5-HT6 Receptor, Ki: 2.04 nM
|
|
|
99.62% |
Agomelatine hydrochloride |
|
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
99.98% |
MK-212 monohydrochloride |
|
|
|
|
|
|
|
|
99.62% |
Vabicaserin hydrochloride |
|
5-HT2C Receptor, EC50: 8 nM
|
|
|
|
|
|
|
99.92% |
RS 67333 hydrochloride |
|
|
|
|
|
|
|
|
99.73% |
5-Carboxamidotryptamine maleate |
5-HT1A Receptor
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
99.73% |
(Rac)-WAY-161503 |
|
5-HT2C Receptor, Ki: 4 nM
5-HT2C Receptor, EC50: 12 nM
|
|
|
|
|
|
|
98.49% |
Intepirdine |
|
|
|
|
|
5-HT6 Receptor, pKi: 9.63
|
|
|
98.92% |
Cyclobenzaprine hydrochloride |
|
|
|
|
|
|
|
|
99.59% |
BMY 7378 |
|
|
|
|
|
|
|
|
99.92% |
Urapidil hydrochloride |
|
|
|
|
|
|
|
|
99.97% |
Pumosetrag Hydrochloride |
|
|
|
|
|
|
|
|
99.77% |
WAY-181187 |
|
|
|
|
|
5-HT6 Receptor, Ki: 2.2 nM
5-HT6 Receptor, EC50: 6.6 nM
|
|
|
98.07% |
Hypidone hydrochloride |
|
|
|
|
|
|
|
|
99.82% |
Azasetron hydrochloride |
|
|
5-HT3 Receptor, IC50: 0.33 nM
|
|
|
|
|
|
99.78% |
Desmethyl cariprazine |
5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
98.06% |
Frovatriptan succinate hydrate |
5-HT1B Receptor, pEC50: 8.2
|
|
|
|
|
|
|
|
99.60% |
Flopropione |
|
|
|
|
|
|
|
|
98.57% |
RS-127445 |
|
5-HT2B Receptor, pKi: 9.5 nM
|
|
|
|
|
|
|
99.62% |
Deramciclane |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
98.13% |
VUF10166 |
|
|
5-HT3A Receptor, Ki: 0.04 nM
5-HT 3 AB, Ki: 22 nM
|
|
|
|
|
|
99.83% |
Pimethixene maleate |
5-HT1A Receptor, pKi: 7.63
|
5-HT2A Receptor, pKi: 10.22
5-HT2B Receptor, pKi: 10.44
5-HT2C Receptor, pKi: 8.42
|
|
|
|
|
|
|
99.94% |
SB-399885 hydrochloride |
|
|
|
|
|
|
|
|
99.58% |
Arotinolol |
|
|
|
|
|
|
|
|
99.93% |
Valerenic acid |
|
|
|
|
5-HT5A Receptor, IC50: 17.2 μM
|
|
|
|
≥99.0% |
Metoclopramide hydrochloride hydrate |
|
|
5-HT3 Receptor, IC50: 308 nM
|
|
|
|
|
|
99.96% |
Rodatristat |
|
|
|
|
|
|
|
|
99.11% |
PRX-08066 |
|
5-HT2B Receptor, IC50: 3.4 nM
|
|
|
|
|
|
|
|
Eptapirone |
|
|
|
|
|
|
|
|
99.91% |
Xaliproden hydrochloride |
5-HT1A Receptor, IC50: 3 nM
|
|
|
|
|
|
|
|
98.57% |
cis-Urocanic acid |
|
|
|
|
|
|
|
|
99.92% |
Brexpiprazole S-oxide-d8 |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
98.72% |
Eltoprazine hydrochloride |
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
99.90% |
Tianeptine |
|
|
|
|
|
|
|
|
99.84% |
Amperozide |
|
5-HT2A Receptor, Ki: 26 nM
|
|
|
|
|
|
|
98.75% |
Idalopirdine hydrochloride |
|
|
|
|
|
5-HT6 Receptor, Ki: 0.83 nM
|
|
|
99.96% |
Pipamperone |
|
5-HT2A Receptor, pKi: 8.2
5-HT2C Receptor, pKi: 6.9
|
|
|
|
|
|
|
99.89% |
Spiroxatrine |
5-HT1A Receptor, Ki: 3.94 nM
5-HT1B/D Receptor, Ki: 224000 nM
|
5-HT2 Receptor, Ki: 118.5 nM
|
|
|
|
|
|
|
99.18% |
LY266097 hydrochloride |
|
5-HT2B Receptor, pKi: 9.8
5-HT2A Receptor, pKi: 7.7
5-HT2C Receptor, pKi: 7.6
|
|
|
|
|
|
|
99.60% |
BMY-14802 hydrochloride |
|
|
|
|
|
|
|
|
98.02% |
RS 23597-190 |
|
|
|
|
|
|
|
|
99.06% |
Zolmitriptan |
5-HT1B Receptor, Ki: 5.01 nM
5-HT1D Receptor, Ki: 0.63 nM
5-HT1F Receptor, Ki: 63.09 nM
|
|
|
|
|
|
|
|
99.98% |
LY334370 |
5-HT1F Receptor, Ki: 1.6 nM
|
|
|
|
|
|
|
|
99.59% |
DSP-1053 |
5-HT1A Receptor, Ki: 5.05 nM
|
|
|
|
|
|
|
|
99.72% |
Nelotanserin |
|
5-HT2A Receptor, IC50: 1.7 nM
5-HT2C Receptor, IC50: 79 nM
5-HT2B Receptor, IC50: 791 nM
|
|
|
|
|
|
|
99.52% |
Donitriptan |
5-HT1B Receptor, pKi: 9.4
5-HT1D Receptor, pKi: 9.3
|
|
|
|
|
|
|
|
98.06% |
Perospirone hydrochloride |
5-HT1A Receptor, Ki: 2.9 nM
5-HT1 Receptor, Ki: 18 nM
|
5-HT2A Receptor, Ki: 0.6 nM
|
|
|
|
|
|
|
99.94% |
Org-12962 |
|
5-HT2C Receptor, pEC50: 7.01
5-HT2A Receptor, pEC50: 6.38
5-HT2B Receptor, pEC50: 6.28
|
|
|
|
|
|
|
99.93% |
LY-272015 hydrochloride |
|
|
|
|
|
|
|
|
99.54% |
Cefaclor monohydrate |
|
|
|
|
|
|
|
|
99.11% |
Didesmethyl cariprazine |
|
|
|
|
|
|
|
|
99.79% |
p-MPPI hydrochloride |
|
|
|
|
|
|
|
|
99.81% |
SB-200646A |
|
5-HT2B Receptor, pKi: 7.5
5-HT2C Receptor, pKi: 6.9
5-HT2A Receptor, pKi: 5.2
|
|
|
|
|
|
|
99.89% |
PU02 |
|
|
5-HT3A Receptor, IC50: 0.36 μM
5-HT 3 AB, IC50: 0.73 μM
|
|
|
|
|
|
≥99.0% |
Alniditan dihydrochloride |
human 5-HT1B Receptor, IC50: 1.7 nM
human 5-HT1D Receptor, IC50: 1.3 nM
5-HT1B Receptor, Kd: 0.9 nM
5-HT1D Receptor, Kd: 1.2 nM
|
|
|
|
|
|
|
|
99.70% |
(E)-3,4,5-Trimethoxycinnamic acid |
5-HT1A Receptor, IC50: 7.6 μM
|
5-HT2C Receptor, IC50: 2.5 μM
5-HT2A Receptor, IC50: >10 μM
|
|
|
|
5-HT6 Receptor, IC50: >10 μM
|
5-HT7 Receptor, IC50: >10 μM
|
|
99.95% |
YM348 |
|
5-HT2A Receptor, Ki: 13 nM
5-HT2B Receptor, Ki: 2.5 nM
5-HT2C Receptor, Ki: 0.89 nM
5-HT2A Receptor, EC50: 93 nM
5-HT2B Receptor, EC50: 3.2 nM
5-HT2C Receptor, EC50: 1 nM
|
|
|
|
|
|
|
99.15% |
Spiramide |
5-HT1A Receptor, Ki: 50 nM
5-HT1C Receptor, Ki: 4300 nM
|
|
|
|
|
|
|
|
99.23% |
Cerlapirdine |
|
|
|
|
|
|
|
|
98.84% |
Renzapride |
|
|
|
5-HT4 Receptor, Ki: 115 nM
|
|
|
|
|
98.36% |
CP-809101 hydrochloride |
|
5-HT2C Receptor, pEC50: 9.96
5-HT2B Receptor, pEC50: 7.19
5-HT2A Receptor, pEC50: 6.81
|
|
|
|
|
|
|
99.37% |
Isocorynoxeine |
|
5-HT2A Receptor, IC50: 72.4 μM
|
|
|
|
|
|
|
99.52% |
Ondansetron hydrochloride |
|
|
|
|
|
|
|
|
99.94% |
BRL-15572 dihydrochloride |
|
|
|
|
|
|
|
|
99.77% |
Ecopipam hydrobromide |
|
|
|
|
|
|
|
|
≥99.0% |
MT-1207 |
|
5-HT2A Receptor, IC50: 0.27 nM
5-HT2A Receptor, Ki: 0.079 nM
|
|
|
|
|
|
|
99.96% |
Usmarapride free base |
|
|
|
5-HT4 Receptor, EC50: 44 nM
|
|
|
|
|
99.91% |
Ampreloxetine |
|
|
|
|
|
|
|
|
98.49% |
GSK163090 |
5-HT1A Receptor, pKi: 9.4
5-HT1B Receptor, pKi: 8.5
5-HT1D Receptor, pKi: 9.7
|
5-HT2A Receptor, pKi: 6
5-HT2B Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 5.8
|
|
|
|
Human 5-HT6 Receptor, pKi: <5.3
|
Human 5-HT7 Receptor , pKi: 6.8
|
|
99.77% |
Eplivanserin hemifumarate |
|
5-HT2A Receptor, IC50: 5.8 nM
5-HT2C Receptor, IC50: 120 nM
|
|
|
|
|
|
|
98.07% |
WAY-100135 dihydrochloride |
5-HT1A Receptor, IC50: 34 nM
|
|
|
|
|
|
|
|
98.32% |
SB-216641A |
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
≥98.0% |
Adoprazine |
5-HT1A Receptor, pEC50: 9
5-HT1A Receptor, pKi: 9.1
|
|
|
|
|
|
|
|
98.60% |
Temanogrel |
|
5-HT2A Receptor, Ki: 4.9 nM
|
|
|
|
|
|
|
98.14% |
Strictosidinic acid |
|
|
|
|
|
|
|
|
|
GR127935 hydrochloride |
5-HT1B Receptor, pKi: 8.5
5-HT1D Receptor, pIC50: 8.5
|
|
|
|
|
|
|
|
98.1% |
Ro60-0175 |
|
|
|
|
|
|
|
|
99.98% |
Felcisetrag |
|
|
|
huamn 5-HT4(c) Receptor, pKi: 9.4
|
|
|
|
|
99.94% |
Cyamemazine |
|
5-HT2A Receptor, Ki: 1.5 nM
5-HT2C Receptor, Ki: 12 nM
|
5-HT3 Receptor, Ki: 75 nM
|
|
|
|
|
|
99.42% |
E-3620 |
|
|
|
|
|
|
|
|
98.88% |
Piromelatine |
5-HT1A Receptor (Agonist)
5-HT1D Receptor (Agonist)
|
5-HT2B Receptor (Antagonist)
|
|
|
|
|
|
|
99.54% |
Flumexadol |
|
5-HT2C Receptor, Ki: 25 nM
|
|
|
|
|
|
|
99.86% |
Indophagolin |
|
|
|
|
|
5-HT6 Receptor, IC50: 1.0 μM
|
|
|
98.05% |
Urapidil |
|
|
|
|
|
|
|
|
99.30% |
Iferanserin |
|
|
|
|
|
|
|
|
99.74% |
Naronapride |
|
|
|
|
|
|
|
|
99.79% |
OPC-14523 hydrochloride |
5-HT1A Receptor, IC50: 2.3 nM
|
|
|
|
|
|
|
|
99.95% |
Fananserin |
|
5-HT2 Receptor, Ki: 0.37 nM
|
|
|
|
|
|
|
99.97% |
Bemesetron |
|
|
5-HT3 Receptor, IC50: 0.33 nM
|
|
|
|
|
|
≥99.0% |
GR-46611 |
|
|
|
|
|
|
|
|
99.82% |
SB-616234-A |
|
|
|
|
|
|
|
|
98.14% |
Velusetrag hydrochloride |
|
|
|
|
|
|
|
|
98.95% |
Nemonapride |
5-HT1A Receptor, IC50: 34 nM
|
|
|
|
|
|
|
|
99.90% |
TC-2153 |
|
|
|
|
|
|
|
|
98.73% |
UNC9994 |
5-HT1F Receptor, Ki: 26 nM
|
5-HT2A Receptor, Ki: 140 nM
5-HT2B Receptor, Ki: 25 nM
5-HT2C Receptor, Ki: 512 nM
|
|
|
|
|
|
|
98.06% |
ST1936 |
|
5-HT2B Receptor, Ki: 245 nM
|
|
|
|
5-HT6 Receptor, Ki: 13 nM
|
5-HT7 Receptor, Ki: 168 nM
|
|
99.70% |
Pardoprunox hydrochloride |
5-HT1A Receptor, pEC50: 6.3
|
|
|
|
|
|
|
|
99.46% |
Pizotifen malate |
|
|
|
|
|
|
|
|
99.88% |
Cyanopindolol |
5-HT1A Receptor, Ki: 2.1 nM
5-HT1B Receptor, Ki: 3 nM
|
|
|
|
|
|
|
|
|
Rodatristat ethyl |
|
|
|
|
|
|
|
|
≥98.0% |
AVN-492 |
|
|
|
|
|
5-HT6 Receptor, Ki: 91 pM
|
|
|
99.30% |
Usmarapride |
|
|
|
5-HT4 Receptor, EC50: 44 nM
|
|
|
|
|
≥98.0% |
Mosapride citrate dihydrate |
|
|
|
|
|
|
|
|
|
Cariprazine-d6 |
5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
98.00% |
Spiperone hydrochloride |
5-HT1A Receptor, Ki: 49 nM
|
5-HT2A Receptor, Ki: 1 nM
|
|
|
|
|
|
|
99.10% |
MAO-A/5-HT2AR-IN-1 |
|
5-HT2A Receptor, IC50: 0.014 μM
|
|
|
|
|
|
|
99.71% |
Peptide 401 |
|
|
|
|
|
|
|
|
98.26% |
BIMU 8 |
|
|
|
5-HT4 Receptor, EC50: 18 nM
|
|
|
|
|
≥99.0% |
SKF-83566 hydrobromide |
|
5-HT2 Receptor, Ki: 11 nM
|
|
|
|
|
|
|
|
Pruvanserin |
|
|
|
|
|
|
|
|
99.27% |
RS 39604 |
|
|
|
|
|
|
|
|
≥98.0% |
4F 4PP oxalate |
|
5-HT2A Receptor, Ki: 5.3 nM
5-HT2C Receptor, Ki: 620 nM
|
|
|
|
|
|
|
98.08% |
SB 243213 dihydrochloride |
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
≥99.0% |
Capeserod |
|
|
|
5-HT4 Receptor, Ki: 0.6 nM
|
|
|
|
|
98.66% |
Robalzotan hydrochloride |
|
|
|
|
|
|
|
|
99.5% |
NPS ALX Compound 4a |
|
|
|
|
|
5-HT6 Receptor, IC50: 7.2 nM
5-HT6 Receptor, Ki: 0.2 nM
|
|
|
≥99.0% |
PNU-142633 |
5-HT1D Receptor, Ki: 6 nM
|
|
|
|
|
|
|
|
98.6% |
Fabesetron |
|
|
|
|
|
|
|
|
|
FPT |
5-HT1A Receptor, IC50: 39.3 nM
5-HT1B Receptor, IC50: 1.2 nM
5-HT1D Receptor, IC50: 0.5 nM
5-HT1A Receptor, Ki: 4.3 nM
5-HT1B Receptor, Ki: 2.3 nM
5-HT1D Receptor, Ki: 1.2 nM
5-HT1F Receptor, Ki: >10,000 nM
|
|
|
|
|
|
|
|
98.06% |
PF-04995274 |
|
|
|
|
|
|
|
|
99.95% |
Isopteropodine |
|
|
|
|
|
|
|
|
98.66% |
Cinanserin hydrochloride |
|
5-HT2 Receptor, Ki: 41 nM
|
|
|
|
|
|
|
99.48% |
EMD 56551 |
|
|
|
|
|
|
|
|
|
PRX-07034 hydrochloride |
5-HT1A Receptor, Ki: 420 nM
5-HT1B Receptor, Ki: 260 nM
5-HT1D Receptor, Ki: 2.8 μM
|
5-HT2A Receptor, IC50: 2.5 μM
5-HT2B Receptor, IC50: 2.5 μM
5-HT2C Receptor, IC50: 3.7 μM
|
|
|
|
5-HT6 Receptor, Ki: 4-8 nM
5-HT6 Receptor, IC50: 19 nM
|
|
|
98.97% |
5-HT1A modulator 1 |
|
5-HT2A Receptor, IC50: 500 nM
5-HT2C Receptor, IC50: 4000 nM
|
|
|
|
|
|
|
|
S-14506 hydrochloride |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
99.92% |
Flibanserin hydrochloride (propan-2-ol) hydrate |
5-HT1A Receptor, Ki: 1 nM
|
5-HT2A Receptor, Ki: 49 nM
|
|
|
|
|
|
|
99.04% |
5-Methoxytryptamine hydrochloride |
|
|
|
|
|
|
|
|
≥98.0% |
SB 243213 hydrochloride |
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
|
BMY 14802 |
|
|
|
|
|
|
|
|
98.96% |
Eplivanserin (mixture) |
|
|
|
|
|
|
|
|
99.77% |
OPC-14523 free base |
5-HT1A Receptor, IC50: 2.3 nM
|
|
|
|
|
|
|
|
|
Repinotan |
5-HT1A Receptor, Ki: 0.19 nM (In calf hippocampus)
5-HT1A Receptor, Ki: 0.25 nM (In rat and human cortex)
5-HT1A Receptor, Ki: 0.59 nM (In rat hippocampus)
|
|
|
|
|
|
|
|
|
(R)-Mirtazapine |
|
|
|
|
|
|
|
|
99.79% |
F 13714 fumarate |
|
|
|
|
|
|
|
|
99.05% |
5-HT2A antagonist 1 |
|
|
|
|
|
|
|
|
|
CJ033466 |
|
|
|
5-HT4 Receptor, EC50: 9 nM
|
|
|
|
|
98.29% |
Lecozotan hydrochloride |
5-HT1A Receptor, Ki: 4.5 nM
|
|
|
|
|
|
|
|
98.71% |
Almotriptan |
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
99.94% |
AP521 |
5-HT1A Receptor, IC50: 94 nM (in human)
5-HT1A Receptor, IC50: 135 nM (in rat)
5-HT1B Receptor, IC50: 254 nM (in rat)
5-HT1B Receptor, IC50: 5530 nM (in human)
5-HT1D Receptor, IC50: 418 nM (in human)
|
|
|
|
5-HT5A Receptor, IC50: 422 nM (in human)
|
|
5-HT7 Receptor, IC50: 198 nM (in rat)
|
|
98.96% |
Revexepride |
|
|
|
|
|
|
|
|
99.84% |
Ro60-0175 fumarate |
|
|
|
|
|
|
|
|
99.47% |
(S)-Amisulpride |
|
|
|
|
|
|
5-HT7 Receptor, Ki: 900 nM
|
|
99.75% |
SB228357 |
|
5-HT2A Receptor, pKi: 6.9
5-HT2C Receptor, pKi: 9
5-HT2B Receptor, pKi: 8
|
|
|
|
|
|
|
99.43% |
Lesopitron dihydrochloride |
5-HT1A Receptor, IC50: 125 nM (in rat hippocampal membranes)
|
|
|
|
|
|
|
|
≥98.0% |
Tedatioxetine hydrobromide |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
99.83% |
Naluzotan |
5-HT1A Receptor, IC50: 20 nM
5-HT1A Receptor, Ki: 5.1 nM
|
|
|
|
|
|
|
|
98.05% |
Facinicline hydrochloride |
|
|
5-HT3 Receptor, Ki: 1.2 nM
|
|
|
|
|
|
99.66% |
Almotriptan malate |
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
99.53% |
Relenopride hydrochloride |
|
5-HT2A Receptor, Ki: 600 nM
5-HT2B Receptor, Ki: 31 nM
5-HT2B Receptor, IC50: 2.1 μM
|
|
5-HT4 Receptor, Ki: 4.96 nM
|
|
|
|
|
99.85% |
ARC 239 |
5-HT1A Receptor, Ki: 63.1 nM
|
|
|
|
|
|
|
|
99.71% |
LE 300 |
|
|
|
|
|
|
|
|
98.5% |
(R)-Praziquantel-d11 |
|
|
|
|
|
|
|
|
99.57% |
(S)-Mirtazapine |
|
|
|
|
|
|
|
|
99.76% |
Ipsapirone |
|
|
|
|
|
|
|
|
99.87% |
cis-(Z)-Flupentixol dihydrochloride |
|
5-HT2A Receptor, Ki: 7 nM
|
|
|
|
|
|
|
|
Brexpiprazole S-oxide |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
|
LY 344864 racemate |
|
|
|
|
|
|
|
|
98.07% |
Risperidone hydrochloride |
|
5-HT2 Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
|
Viloxazine |
|
Human 5-HT2C Receptor, EC50: 32 μM
human 5-HT2B Receptor, IC50: 27 μM
|
|
|
|
|
|
|
99.15% |
(Rac)-Rotigotine hydrochloride |
5-HT1A Receptor, Ki: 30 nM
|
5-HT2B Receptor, Ki: 27 nM
|
|
|
|
|
|
|
98.66% |
Dolasetron Mesylate hydrate |
|
|
|
|
|
|
|
|
≥99.0% |
Alosetron |
|
|
|
|
|
|
|
|
|
Mosapride |
|
|
|
|
|
|
|
|
99.87% |
(-)-5-HT2C agonist-3 |
|
5-HT2A Receptor, IC50: 72 nM
5-HT2C Receptor, IC50: 103 nM
5-HT2B Receptor, IC50: 570 nM
|
|
|
|
|
|
|
|
Eltoprazine |
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
|
Pimethixene |
5-HT1A Receptor, pKi: 7.63
|
5-HT2A Receptor, pKi: 10.22
5-HT2B Receptor, pKi: 10.44
5-HT2C Receptor, pKi: 8.42
|
|
|
|
|
|
|
|
Ziprasidone hydrochloride |
Rat 5-HT1A Receptor, Ki: 3.4 nM
|
|
|
|
|
|
|
|
|
Palonosetron |
|
|
|
|
|
|
|
|
|
5-HT6/7 antagonist 1 |
|
|
|
|
|
|
|
|
|
Lintopride |
|
|
|
|
|
|
|
|
|
Naratriptan |
|
|
|
|
|
|
|
|
|
(±)-Fabesetron hydrochloride |
|
|
|
|
|
|
|
|
|
Lidanserin |
|
|
|
|
|
|
|
|
≥98.0% |
SB-269970 |
|
|
|
|
|
|
Human 5-HT7 Receptor , pKi: 8.3
|
|
|
AM9405 |
|
|
5-HT3 Receptor, IC50: 0.076 nM
|
|
|
|
|
|
|
SEP-363856 |
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
|
|
|
|
5-HT7 Receptor, EC50: 6.7 μM
|
|
|
Clocapramine |
|
|
|
|
|
|
|
|
|
Blonanserin dihydrochloride |
|
5-HT2A Receptor, Ki: 0.812 nM
5-HT2C Receptor, Ki: 26.4 nM
|
|
|
|
5-HT6 Receptor, Ki: 11.7 nM
|
|
|
|
UCSF648 |
|
|
|
|
|
|
|
|
|
SB 271046 |
|
|
|
|
|
5-HT6 Receptor, pKi: 8.92-9.09
|
|
|
|
Metoclopramide hydrochloride |
|
|
5-HT3 Receptor, IC50: 308 nM
|
|
|
|
|
|
|
CYB210010 |
5-HT1A Receptor, Ki: 32 nM
5-HT1B Receptor, Ki: 949 nM
|
5-HT2A Receptor, EC50: 4.1 nM
5-HT2C Receptor, EC50: 7.3 nM
5-HT2B Receptor, EC50: 88 nM
|
|
|
|
5-HT6 Receptor, Ki: 1301 nM
|
5-HT7 Receptor, Ki: 4918 nM
|
|
|
Scopolamine hydrochloride |
|
|
5-HT3 Receptor, IC50: 2.09 μM
|
|
|
|
|
|
|
LY334370 hydrochloride |
5-HT1F Receptor, Kd: 0.446 nM
|
|
|
|
|
|
|
|
|
RU 24969 hemisuccinate |
5-HT1A Receptor, Ki: 2.5 nM
5-HT1B Receptor, Ki: 0.38 nM
|
|
|
|
|
|
|
|
|
DV-7028 hydrochloride |
|
|
|
|
|
|
|
|
|
PF-03382792 |
|
|
|
5-HT4d Receptor, Ki: 2.7 nM
5-HT4d Receptor, EC50: 0.9 nM
|
|
|
|
|
|
CP-135807 |
5-HT1D Receptor, IC50: 3.1 nM (rat)
5-HT1D Receptor, IC50: 33 nM (bovine)
|
|
|
|
|
|
|
|
|
RS-102221 |
|
5-HT2C Receptor, Ki: 10 nM
|
|
|
|
|
|
|
|
Etoperidone hydrochloride |
5-HT1A Receptor, Kd: 85 nM
|
5-HT2 Receptor, Kd: 36 nM
|
|
|
|
|
|
|
|
LY320135 |
|
5-HT2 Receptor, Ki: 6.4 μM
|
|
|
|
|
|
|
|
Aripiprazole monohydrate |
|
5-HT2A Receptor
5-HT2B Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
|
PD 158771 |
human 5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
|
E6801 |
|
|
|
|
|
|
|
|
|
Risperidone-d6 |
|
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
|
U92016A hydrochloride |
5-HT1A Receptor, Ki: 0.2 nM
|
|
|
|
|
|
|
|
|
WAY 163909 |
|
5-HT2C Receptor, Ki: 10.5±1.1 nM
|
|
|
|
|
|
|
|
PRX933 hydrochloride |
|
|
|
|
|
|
|
|
|
PRX-08066 maleate |
|
5-HT2B Receptor, IC50: 3.4 nM
|
|
|
|
|
|
|
|
GSK215083 |
|
|
|
|
|
|
|
|
|
Methylergometrine |
|
|
|
|
|
|
|
|
|
Robalzotan |
|
|
|
|
|
|
|
|
|
Blonanserin-d5 |
|
|
|
|
|
|
|
|
|
5-HT6/5-HT2A receptor ligand-2 |
|
5-HT2A Receptor, Ki: 32 nM
|
|
|
|
5-HT6 Receptor, Ki: 25 nM
|
|
|
|
Eletriptan |
5-HT1B Receptor, pKi: 8.0
5-HT1D Receptor, pKi: 8.9
|
|
|
|
|
|
|
|
|
(+)-Norcisapride |
|
|
|
|
|
|
|
|
|
SB-215505 |
|
5-HT2B Receptor, pKi: 8.3
5-HT2A Receptor, pKi: 6.77
5-HT2C Receptor, pKi: 7.66
|
|
|
|
|
|
|
98.91% |
PNU-96415E |
|
|
|
|
|
|
|
|
|
PNU-282987 free base |
|
|
|
|
|
|
|
|
|
5-HT6/5-HT2A receptor ligand-1 |
|
5-HT2A Receptor, IC50: 11 nM
|
|
|
|
|
|
|
|
PF-03246799 |
|
5-HT2C Receptor, EC50: 190 nM
5-HT2C Receptor, Ki: 160 nM
|
|
|
|
|
|
|
|
Syk Inhibitor II hydrochloride |
|
|
|
|
|
|
|
5-HT Receptor, IC50: 460 nM
|
|
SB 258719 hydrochloride |
|
|
|
|
|
|
|
|
|
Dehydro Palonosetron |
|
|
|
|
|
|
|
|
|
Brexpiprazole hydrochloride |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
|
2-Methyl-5-HT hydrochloride |
|
|
|
|
|
|
|
|
|
ZINC866533340 |
|
5-HT2A Receptor, Ki: 1.6 nM
|
|
|
|
|
|
|
|
Dehydroaripiprazole hydrochloride |
5-HT1A Receptor, Ki: 4.2 nM
|
|
|
|
|
|
|
|
|
Eptapirone fumarate |
|
|
|
|
|
|
|
|
|
LY215840 |
|
|
|
|
|
|
|
|
|
SUN C5174 |
|
|
|
|
|
|
|
|
|
5-HT6/5-HT2AR antagonist-1 |
|
5-HT2A Receptor, Ki: 39 nM
|
|
|
|
5-HT6 Receptor, Ki: 11 nM
|
|
|
|
BRL-15572 hydrochloride |
|
|
|
|
|
|
|
|
|
SB-221284 |
|
5-HT2A Receptor, pKi: 6.4
5-HT2B Receptor, pKi: 7.9
5-HT2C Receptor, pKi: 8.6
|
|
|
|
|
|
|
|
Isamoltane hemifumarate |
5-HT1B Receptor, IC50: 39 nM
|
|
|
|
|
|
|
|
|
Tandospirone hydrochloride |
5-HT1A Receptor, Ki: 27 nM
|
|
|
|
|
|
|
|
|
MR33317 |
|
|
|
|
|
|
|
|
|
GM-60186 |
|
5-HT2B Receptor, IC50: 257 nM
|
|
|
|
|
|
|
|
MK-212 |
|
|
|
|
|
|
|
|
|
Blonanserin-d8 |
|
|
|
|
|
|
|
|
|
5-HT7 receptor ligand 1 |
|
|
|
|
|
|
|
|
|
SCH-23390 maleate |
|
5-HT2C Receptor, Ki: 9.3 nM
|
|
|
|
|
|
|
|
7-Desmethyl-3-hydroxyagomelatine |
|
|
|
|
|
|
|
|
|
MAO-B-IN-3 |
|
|
|
|
|
Human 5-HT6 Receptor, Ki: 696 nM
|
|
|
|
WAY-181187 oxalate |
|
|
|
|
|
5-HT6 Receptor, Ki: 2.2 nM
5-HT6 Receptor, EC50: 6.6 nM
|
|
|
|
SEP-363856 mesylate |
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
|
|
|
|
5-HT7 Receptor, EC50: 6.7 μM
|
|
|
SB399885 |
|
|
|
|
|
5-HT6 Receptor, pKi: 9.02
Human 5-HT6 Receptor, pKi: 9.11
|
|
|
|
DSP-1053 benzenesulfonate |
5-HT1A Receptor, Ki: 5.05 nM
|
|
|
|
|
|
|
|
|
1-(1-Naphthyl)piperazine hydrochloride |
|
|
|
|
|
|
|
|
|
Ecopipam |
|
|
|
|
|
|
|
|
|
Cinitapride monotartrate |
|
|
|
|
|
|
|
|
|
5-HT7R antagonist 2 |
|
|
|
|
|
|
5-HT7 Receptor, Ki: 67 nM
|
|
|
Asimilobine |
|
|
|
|
|
|
|
|
|
5-HT2A antagonist 2 |
|
5-HT2A Receptor, IC50: 14 nM
|
|
|
|
|
|
|
|
LP 12 hydrochloride |
5-HT1A Receptor, IC50: 60.9 nM
|
5-HT2A Receptor, IC50: 1464 nM
|
|
|
|
|
5-HT7 Receptor, IC50: 0.13 nM
|
|
|
Mesulergine hydrochloride |
|
|
|
|
|
|
|
|
|
WAY-181187 hydrochloride |
|
|
|
|
|
5-HT6 Receptor, Ki: 2.2 nM
5-HT6 Receptor, EC50: 6.6 nM
|
|
|
|
Trimipramine |
5-HT1C Receptor, pKi: 6.39
5-HT1A Receptor, pKi: 4.66
|
5-HT2 Receptor, pKi: 8.10
|
|
|
|
|
|
|
|
Bifeprunox |
5-HT1A Receptor, pKi: 7.19 (cortex)
5-HT1A Receptor, pEC50: 6.37 (hippocampus)
|
|
|
|
|
|
|
|
|
Goxalapladib |
|
|
|
|
|
|
|
|
|
5-HT6R antagonist 3 |
5-HT1A Receptor, Ki: 3533 nM
|
5-HT2A Receptor, Ki: 35 nM
|
|
|
|
5-HT6 Receptor, Ki: 14 nM
|
5-HT7 Receptor, Ki: 1449 nM
|
|
|
Eplivanserin |
|
5-HT2A Receptor, IC50: 5.8 nM (in rat cortical membrane)
5-HT2A Receptor, Ki: 1.14 nM
5-HT2C Receptor, IC50: 120 nM
|
|
|
|
|
|
|
|
EMD386088 |
|
|
|
|
|
|
|
|
99.06% |
Ro 04-6790 |
|
|
|
|
|
Rat 5-HT6 Receptor, pKi: 7.26
Human 5-HT6 Receptor, pKi: 7.35
|
|
|
|
3-Hydroxy agomelatine-d3 |
|
5-HT2C Receptor, IC50: 3.2 μM
5-HT2C Receptor, Ki: 1.8 μM
|
|
|
|
|
|
|
99.92% |
ST1936 oxalate |
|
5-HT2B Receptor, Ki: 245 nM
|
|
|
|
5-HT6 Receptor, Ki: 13 nM
|
Human 5-HT7 Receptor , Ki: 168 nM
|
|
|
(R)-Mirtazapine-d3 |
|
|
|
|
|
|
|
|
|
LY320954 |
|
5-HT2A Receptor, Ki: 96 nM
5-HT2B Receptor, Ki: 1642 nM
5-HT2C Receptor, Ki: 257 nM
|
|
|
|
|
|
|
|
SB 258741 hydrochloride |
|
|
|
|
|
|
|
|
|
GR127935 |
|
|
|
|
|
|
|
|
|
Elzasonan hydrochloride |
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
|
3-AQC |
|
|
|
|
|
|
|
|
|
Syk Inhibitor II dihydrochloride |
|
|
|
|
|
|
|
5-HT Receptor, IC50: 460 nM
|
|
5-Carboxamidotryptamine |
5-HT1A Receptor
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
|
5-HT1A antagonist 1 |
5-HT1A Receptor, Ki: 35 nM
|
5-HT2A Receptor, Ki: 530 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 462 nM
|
|
|
Ziprasidone mesylate trihydrate |
Rat 5-HT1A Receptor, Ki: 3.4 nM
|
Rat 5-HT2 Receptor, Ki: 0.42 nM
|
|
|
|
|
|
|
|
AR-A 2 |
5-HT1A Receptor, Ki: 3070 nM
5-HT1B/D Receptor, Ki: 20 nM
|
5-HT2A Receptor, Ki: 339 nM
|
|
|
|
|
|
|
|
Flucopride |
|
|
|
huamn 5-HT4(c) Receptor, Ki: 9.6 nM
|
|
|
|
|
|
Sarpogrelate |
|
|
|
|
|
|
|
|
|
(Rac)-WAY-161503 hydrochloride |
|
5-HT2C Receptor, Ki: 4 nM
5-HT2C Receptor, EC50: 12 nM
|
|
|
|
|
|
|
|
BMY 28674 |
Rat 5-HT1A Receptor, EC50: 4 μM
Rat 5-HT1A Receptor, EC50: 1 μM
|
|
|
|
|
|
|
|
|
LY 278584 |
|
|
5-HT3 Receptor, Ki: 1.62 nM
|
|
|
|
|
|
|
NAN-190 |
|
|
|
|
|
|
|
|
|
Asenapine citrate |
5-HT1A Receptor, pKi: 8.6
5-HT1B Receptor, pKi: 8.4
|
5-HT2A Receptor, pKi: 10.2
5-HT2B Receptor, pKi: 9.8
5-HT2C Receptor, pKi: 10.5
|
|
|
|
|
|
|
|
Piclozotan |
|
|
|
|
|
|
|
|
|
Mesembrine |
|
|
|
|
|
|
|
|
|
S-14671 |
5-HT1A Receptor, pKi: 9.3
|
|
|
|
|
|
|
|
|
Lintopride hydrochloride |
|
|
|
|
|
|
|
|
|
CART(62-76)(human,rat) |
|
|
|
|
|
|
|
|
|
DR4485 hydrochloride |
|
|
|
|
|
|
5-HT7 Receptor, pKi: 8.14
|
|
|
Cisapride monohydrate |
|
|
|
5-HT4 Receptor, EC50: 0.14 μM
|
|
|
|
|
|
EMDT oxalate |
|
|
|
|
|
|
|
|
|
TIK-301 |
|
5-HT2C Receptor
5-HT2B Receptor
|
|
|
|
|
|
|
|
Loxapine hydrochloride |
|
|
|
|
|
|
|
|
|
MM 77 dihydrochloride |
|
|
|
|
|
|
|
|
|
Etoperidone |
5-HT1A Receptor, Kd: 85 nM
|
5-HT2A Receptor, Kd: 36 nM
|
|
|
|
|
|
|
|
CP94253 |
5-HT1B Receptor, Ki: 2 nM
5-HT1D Receptor, Ki: 49 nM
5-HT1A Receptor, Ki: 89 nM
5-HT1C Receptor, Ki: 860 nM
|
5-HT2 Receptor, Ki: 1600 nM
|
|
|
|
|
|
|
|
Remlifanserin |
|
|
|
|
|
|
|
|
|
VU6067416 |
|
5-HT2A Receptor, EC50: 189 nM
|
|
|
|
|
|
|
|
Urapidil-d4 |
|
|
|
|
|
|
|
|
|
CP 93129 |
|
|
|
|
|
|
|
|
|
Clocapramine dihydrochloride hydrate |
|
|
|
|
|
|
|
|
|
Opiranserin |
|
5-HT2A Receptor, IC50: 1.3 μM
|
|
|
|
|
|
|
|
BGC20-761 |
|
Human 5-HT2A Receptor, Ki: 69 nM
|
|
|
|
Human 5-HT6 Receptor, Ki: 20 nM
|
|
|
|
5-HT2CR agonist 1 |
|
5-HT2C Receptor, EC50: 121.5 nM
|
|
|
|
|
|
|
|
5-HT7 agonist 1 |
|
|
|
|
|
|
|
|
|
Antipsychotic agent-2 |
5-HT1A Receptor, EC50: 160 nM
|
5-HT2A Receptor, Kb: 96.4 nM
|
|
|
|
|
|
|
|
PF-4479745 |
5-HT1A Receptor, IC50: 500 nM
|
5-HT2C Receptor, EC50: 10 nM
5-HT2C Receptor, Ki: 15 nM
5-HT2A Receptor, IC50: 360 nM
5-HT2B Receptor, IC50: 67 nM
|
|
|
|
5-HT6 Receptor, IC50: 280 nM
|
|
|
|
Syk Inhibitor II dihydrochloride dihydrate |
|
|
|
|
|
|
|
|
|
Ziprasidone mesylate |
Rat 5-HT1A Receptor, Ki: 3.4 nM
|
Rat 5-HT2 Receptor, Ki: 0.42 nM
|
|
|
|
|
|
|
|
NEO 376 |
|
|
|
|
|
|
|
|
99.23% |
MHP 133 |
|
|
|
|
|
|
|
|
|
CART(62-76)(human,rat) TFA |
|
|
|
|
|
|
|
|
|
Perphenazine dihydrochloride |
5-HT1A Receptor, Ki: 421 nM
|
5-HT2A Receptor, Ki: 5.6 nM
5-HT2C Receptor, Ki: 132 nM
|
|
|
|
5-HT6 Receptor, Ki: 17 nM
|
5-HT7 Receptor, Ki: 23 nM
|
|
|
5-HT7R antagonist 3 |
5-HT1A Receptor, Ki: 8930 nM
|
5-HT2A Receptor, Ki: 5786 nM
|
|
|
|
|
|
|
|
AVN-101 hydrochloride |
5-HT1A Receptor, Ki: 61 nM
5-HT1B Receptor, Ki: 720 nM
|
5-HT2C Receptor, Ki: 1.17 nM
5-HT2A Receptor, Ki: 1.56 nM
5-HT2B Receptor, Ki: 10.6 nM
|
|
|
|
5-HT6 Receptor, Ki: 2.04 nM
|
5-HT7 Receptor, Ki: 0.153 nM
|
|
99.59% |
LY 344864 hydrochloride |
human 5-HT1F Receptor, Ki: 0.006 μM
human 5-HT1A Receptor, Ki: 0.530 μM
human 5-HT1B Receptor, Ki: 0.549 μM
human 5-HT1D Receptor, Ki: 0.575 μM
human 5-HT1E Receptor, Ki: 1.415 μM
|
human 5-HT2B Receptor, Ki: 1.695 μM
Human 5-HT2C Receptor, Ki: 3.499 μM
|
Human 5-HT3A Receptor, Ki: 3.935 μM
|
|
|
|
Human 5-HT7 Receptor , Ki: 4.851 μM
|
|
|
Donitriptan hydrochloride |
5-HT1B Receptor, pKi: 9.4
5-HT1D Receptor, pKi: 9.3
|
|
|
|
|
|
|
|
|
CGS 12066 dimaleate |
5-HT1B Receptor, IC50: 51 nM
|
|
|
|
|
|
|
|
|
5-HT3 antagonist 5 |
|
|
|
|
|
|
|
|
99.75% |
Sumatriptan hydrochloride |
5-HT1D Receptor, Ki: 17 nM
5-HT1B Receptor, Ki: 27 nM
5-HT1A Receptor, Ki: 100 nM
5-HT1D Receptor, IC50: 7.3 nM
5-HT1B Receptor, IC50: 9.3 nM
5-HT1F Receptor, IC50: 17.8 nM
|
|
|
|
|
|
|
|
|
SGS518 oxalate |
|
|
|
|
|
|
|
|
|
Org-12962 hydrochloride |
|
5-HT2C Receptor, pEC50: 7.01
5-HT2A Receptor, pEC50: 6.38
5-HT2B Receptor, pEC50: 6.28
|
|
|
|
|
|
|
|
WAY 629 |
|
5-HT2C Receptor, EC50: 426 nM
5-HT2A Receptor, EC50: 260000 nM
|
|
|
|
|
|
|
|
Lurosetron |
|
|
|
|
|
|
|
|
|
ML 10302 hydrochloride |
|
|
5-HT3 Receptor, Ki: 782 nM
|
5-HT4 Receptor, EC50: 4 nM
5-HT4 Receptor, Ki: 1.07 nM
|
|
|
|
|
|
NPS ALX Compound 4a dihydrochloride |
|
|
|
|
|
5-HT6 Receptor, IC50: 7.2 nM
5-HT6 Receptor, Ki: 0.2 nM
|
|
|
|
Frovatriptan succinate |
5-HT1B Receptor, pEC50: 8.2
|
|
|
|
|
|
|
|
|
Ramosetron |
|
|
|
|
|
|
|
|
|
SB-200646 |
|
5-HT2B Receptor, pKi: 7.5
5-HT2C Receptor, pKi: 6.9
5-HT2A Receptor, pKi: 5.2
|
|
|
|
|
|
|
|
BL-1020 mesylate |
|
5-HT2A Receptor, Ki: 3.74 μM
|
|
|
|
|
|
|
|
5-HT4 antagonist 1 |
|
|
|
|
|
|
|
|
98.67% |
Carpindolol |
5-HT1B Receptor, pKd: 8.53
5-HT1D Receptor, pEC50: 5.91
5-HT1D Receptor, pKd: 6.37
|
|
|
|
|
|
|
|
|
5-HT6R/MAO-B modulator 1 |
|
|
|
|
|
|
|
|
|
WAY 629 hydrochloride |
|
5-HT2C Receptor, EC50: 426 nM
5-HT2A Receptor, EC50: 260000 nM
|
|
|
|
|
|
|
|
Masupirdine free base |
|
|
|
|
|
5-HT6 Receptor, Ki: 2.04 nM
|
|
|
|
SB-737050A |
|
|
|
|
|
|
|
|
|
RS-64459-193 |
5-HT1A Receptor, Ki: 24.9 nM (CHO cells)
human 5-HT1A Receptor, pKi: 7.6 (Sf9)
human 5-HT1A Receptor, pKi: 7.04
|
5-HT2C Receptor, pKi: 6.87
Rat 5-HT2A, pKi: 7.02
|
|
|
|
|
Human 5-HT7 Receptor , pKi: 7.18
|
|
|
DU125530 |
5-HT1A Receptor, Ki: 0.7 nM
5-HT1B Receptor, Ki: 890 nM
5-HT1C Receptor, Ki: 1200 nM
|
5-HT2A Receptor, Ki: 240 nM
5-HT2C Receptor, Ki: 750 nM
|
5-HT3 Receptor, Ki: 1100 nM
|
|
|
|
|
|
|
5HT6-ligand-2 |
|
|
|
|
|
|
|
|
|
2-Methyl-5-HT maleate |
|
|
|
|
|
|
|
|
|
F 13714 |
5-HT1A Receptor, pKi: 10.23
5-HT1B Receptor, pIC50: 5.12
|
|
|
|
|
|
|
|
|
YM-31636 free base |
5-HT1F Receptor, Ki: >10000 nM
|
5-HT2A Receptor, Ki: >10000 nM
|
5-HT3 Receptor, Ki: 0.2 nM
|
|
|
|
|
|
|
VER-3323 |
|
|
|
|
|
|
|
|
|
R-137696 |
|
|
|
|
|
|
|
|
|
Risperidone mesylate |
|
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
|
Adatanserin |
5-HT1A Receptor, Ki: 1 nM
|
5-HT2 Receptor, Ki: 73 nM
|
|
|
|
|
|
|
|
Serazapine |
|
|
|
|
|
|
|
|
|
PF-05212377 |
|
|
|
|
|
|
|
|
|
Iloperidone hydrochloride |
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 nM
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
|
GTS-21 |
|
|
5-HT3A Receptor, IC50: 3.1 μM
|
|
|
|
|
|
|
Cinanserin |
5-HT1 Receptor, Ki: 3500 nM
|
5-HT2 Receptor, Ki: 41 nM
|
|
|
|
|
|
|
|
Agomelatine (L(+)-Tartaric acid) |
|
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
99.82% |
Alosetron ((Z)-2-butenedioate) |
|
|
|
|
|
|
|
|
|
Zalospirone |
|
|
|
|
|
|
|
|
|
Fabesetron hydrochloride |
|
|
|
|
|
|
|
|
|
Ro 63-0563 |
|
|
|
|
|
Rat 5-HT6 Receptor, pKi: 7.83
Human 5-HT6 Receptor, pKi: 7.91
|
|
|
|
MS 245 |
|
|
|
|
|
5-HT6 Receptor, Ki: 1.5 nM
|
|
|
|
Pardoprunox |
5-HT1A Receptor, pEC50: 6.3
|
|
|
|
|
|
|
|
|
Sarizotan dihydrochloride |
5-HT1A Receptor, IC50: 0.1 nM
|
5-HT2A Receptor, IC50: 587 nM
5-HT2B Receptor, IC50: 108 nM
|
|
|
5-HT5A Receptor, IC50: 313 nM
|
Human 5-HT6 Receptor, IC50: 3300 nM
|
Human 5-HT7 Receptor , IC50: 10 nM
|
|
|
Itasetron |
|
|
|
|
|
|
|
|
|
Dolasetron Mesylate |
|
|
|
|
|
|
|
|
|
(R)-Praziquantel |
|
|
|
|
|
|
|
|
|
SC-53116 |
|
|
|
5-HT4 Receptor, EC50: 23 nM
|
|
|
|
|
|
S14063 |
|
|
|
|
|
|
|
|
|
Alosetron (Hydrochloride(1:X)) |
|
|
|
|
|
|
|
|
|
Cloroperone |
|
|
|
|
|
|
|
|
|
SB-272183 |
5-HT1A Receptor, pKi: 8.0
5-HT1B Receptor, pKi: 8.1
5-HT1D Receptor, pKi: 8.7
|
|
|
|
|
|
|
|
|
R(+)-8-OH-DPAT hydrobromide |
|
|
|
|
|
|
|
|
|
Phenylbiguanide hydrochloride |
|
|
5-HT3 Receptor, EC50: 3 μM
|
|
|
|
|
|
|
EGIS-7625 |
|
5-HT2B Receptor, pKi: 9.0
5-HT2A Receptor, pKi: 6.2
5-HT2C Receptor, pKi: 7.7
|
|
|
|
|
|
|
|
Capeserod hydrochloride |
|
|
|
5-HT4(e) Receptor, Ki: 0.6 nM
|
|
|
|
|
|
Idalopirdine |
|
|
|
|
|
5-HT6 Receptor, Ki: 0.83 nM
|
|
|
|
Piboserod hydrochloride |
|
|
|
|
|
|
|
|
|
Beloxepin |
|
|
|
|
|
|
|
|
|
Nexopamil racemate |
|
|
|
|
|
|
|
|
|
Abaperidone |
|
5-HT2A Receptor, IC50: 6.2 nM
|
|
|
|
|
|
|
|
Irindalone |
|
|
|
|
|
|
|
|
|
Pancopride |
|
|
|
|
|
|
|
|
|
Sulamserod |
|
|
|
|
|
|
|
|
|
Alniditan |
human 5-HT1B Receptor, IC50: 1.7 nM (in HEK 293 cell)
human 5-HT1D Receptor, IC50: 1.3 nM (in HEK 293 cell)
5-HT1B Receptor, Kd: 0.9 nM
5-HT1D Receptor, Kd: 1.2 nM
|
|
|
|
|
|
|
|
|
RG-12915 |
|
|
5-HT3 Receptor, IC50: 0.16 nM
|
|
|
|
|
|
|
NRA-0160 |
|
5-HT2A Receptor, Ki: 180 nM (in rat)
|
|
|
|
|
|
|
|
Wf-516 |
5-HT1A Receptor, Ki: 5 nM
|
5-HT2A Receptor, Ki: 40 nM
|
|
|
|
|
|
|
|
T 82 |
|
|
|
|
|
|
|
|
|
DA-6886 monohydrochloride |
|
|
|
5-HT4 Receptor, pIC50: 4.3
|
|
|
|
|
|
Sulamserod hydrochloride |
|
|
|
|
|
|
|
|
|
WAY-100289 |
|
|
|
|
|
|
|
|
|
Clozapine hydrochloride |
|
5-HT2A Receptor, Ki: 4 nM
|
|
|
|
|
|
|
|
CP-809101 |
|
5-HT2C Receptor, pEC50: 9.96
5-HT2B Receptor, pEC50: 7.19
5-HT2A Receptor, pEC50: 6.81
|
|
|
|
|
|
|
|
5-HT3 antagonist 3 |
|
|
5-HT3 Receptor, Ki: 0.25 nM
|
|
|
|
|
|
|
Zatosetron maleate |
|
|
|
|
|
|
|
|
|
(4E)-SUN9221 |
|
|
|
|
|
|
|
|
|
5-HT3 antagonist 1 |
|
|
|
|
|
|
|
|
|
5-HT3-In-1 |
|
|
|
|
|
|
|
|
|
5-HT2 antagonist 1 |
|
|
|
|
|
|
|
|
|
5-HT3 antagonist 2 |
|
|
|
|
|
|
|
|
|
5HT6-ligand-1 |
|
|
|
|
|
5-HT6 Receptor, Ki: 1.43 nM
|
|
|
|